Brovincamine
Brovincamine is an orally active slow Ca2+ channel blocker and vasodilator. Brovincamine reduces Ca2+ influx across the plasma membrane by blocking Ca2+ channels. Brovincamine inhibits catecholamine secretion, cholinergic function, autonomic parasympathetic nervous system activity, cerebrovascular resistance, and nerve stimulation-induced convulsive responses. Brovincamine induces cerebrovascular, coronary, and intracranial vasodilation, improves cerebral cortical microcirculation, enhances cerebral metabolic activity, and increases capillary clearance efficiency. Brovincamine can be used in research related to cerebral ischemic diseases, cardiac ischemic diseases, and normal-tension glaucoma.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 57475-17-9
- 화학식: C21H25BrN2O3
- 분자량:433.35
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Calcium Channel Isoforms
More
Biological Activity
제품 설명
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Brovincamine (2-4 mg/kg, intravenous injection; single/cumulative administration) slightly but dose-dependently inhibits ganglionic stimulant-induced tachycardia in spinal dogs[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mongrel dogs (either sex, weighing 6-12 kg, spinal model)[2]
-
Dosage:6.4 mg/kg
-
Administration:i.v.; single dose
-
Result:Slightly inhibited the increases in blood pressure and heart rate induced by i.v. DMPP.
-
Animal Model:Mongrel dogs (either sex, weighing 6-12 kg, spinal model)[2]
-
Dosage:2 mg/kg; 4 mg/kg
-
Administration:i.v.; single dose; cumulative
-
Result:Induced a slight but stepwise inhibition of tachycardia elicited by DMPP, BCH, and AT II delivered to cardiac sympathetic ganglia.
Significantly reduced positive chronotropic responses to AT II.
-
Animal Model:OFA (Sprague Dawley) (female; 12 months, 36 months)[4]
-
Dosage:7.5 mg/kg/day
-
Administration:p.o.; daily; 4 weeks
-
Result:Reduced capillary diameter from 3.20 μm to 2.97 μm in 12-month-old rats.
Increased capillary volume fraction from 3.62% to 4.46% in 12-month-old rats.
Reduced mean intercapillary distance from 30.90 μm to 27.79 μm in 12-month-old rats.
Increased capillary length per unit cortex from 54.87 cm/mm3 to 69.03 cm/mm3 in 12-month-old rats.
Increased number of capillaries per measuring field from 20 to 23 in 12-month-old rats.
Reduced capillary diameter from 3.29 μm to 3.09 μm in 36-month-old rats.
Increased capillary volume fraction from 3.67% to 4.45% in 36-month-old rats.
Reduced mean intercapillary distance from 31.04 μm to 28.78 μm in 36-month-old rats.
Increased capillary length per unit cortex from 50.77 cm/mm3 to 71.15 cm/mm3 in 36-month-old rats.
Increased number of capillaries per measuring field from 19 to 23 in 36-month-old rats.
Chemical Information
-
CAS No. 57475-17-9
-
분자량 433.35
-
화학식 C21H25BrN2O3
-
SMILES
C(C)[C@]12[C@]3(C=4N(C=5C(C4CCN3CCC1)=CC=C(Br)C5)[C@](C(OC)=O)(O)C2)[H]
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)